IL6 and non-small cell lung carcinoma: Shi et al. observed correlations with peripheral blood-based markers and survival in advanced non-small cell lung cancer patients who received immunotherapy-based treatments and revealed an increase of Il-6 during treatment and an association with poor prognosis [32].